Oct 2026· American Journal of Cardiology· 0 citations· 33 references
Medicine
TL;DR
In conclusion, genetic testing for HTAD remains markedly underutilized, with < 2.5% of at-risk patients tested despite guideline recommendations, highlighting persistent implementation gaps and the need to improve equitable access to genetic evaluation.
Abstract
Heritable thoracic aortic diseases (HTAD) include genetic conditions that increase risk of thoracic aortic aneurysm and dissection. The 2022 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend genetic testing for at-risk individuals, but real-world uptake remains unclear. We evaluated adherence to testing recommendations and demographic differences across major HTAD risk cohorts. We conducted a retrospective study using the TriNetX Research Network (2005-2025). Three guideline-based cohorts were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes: (1) thoracic aortic aneurysm/dissection before age 60, (2) family history of thoracic aortic disease, and (3) non-thoracic arterial aneurysms. Genetic testing was defined by ICD-10-CM codes for genetic screening or susceptibility. Testing prevalence was stratified by age, sex, race, and ethnicity, and annual testing incidence (2005-2024) was evaluated. Among 57,935 patients with thoracic aortic aneurysm/dissection before age 60, 1,205 (2.09%) underwent genetic testing. Among 2,811,862 patients with a family history of thoracic aortic disease, 66,699 (2.38%) received testing. Among 347,000 patients with non-thoracic arterial aneurysms, 4,913 (1.42%) underwent testing. Testing was consistently higher in females than males and varied across age groups. Annual testing incidence increased over time but remained <0.6% by 2024. In conclusion, genetic testing for HTAD remains markedly underutilized, with < 2.5% of at-risk patients tested despite guideline recommendations, highlighting persistent implementation gaps and the need to improve equitable access to genetic evaluation.
The frequency of cascade family screening in the current era with either cardiovascular imaging (cascade cardiac screening) and/or genetic testing (cascade genetic screening) and the impact of such testing on adverse outcomes in first degree family members was evaluated.
Bradley J. Schwartz, L. Starr, Drew M. Cratsenberg et al.· Pediatric Cardiology· 0 citations
BACKGROUND
Genetic testing increasingly identifies variants of uncertain significance (VUS) in patients with thoracic aortic disease. Treated as benign, VUS impact on outcomes remains unclear. We evaluated associations between genetic variants and surgical outcomes in patients undergoing aortic surgery.
METHODS
This...
Sedem Dankwa, T. Phu, Ely Erez et al.· Annals of Thoracic Surgery· 0 citations
Bicuspid aortic valve (BAV) affects 0.8% of the population and demonstrates high heritability with up to 89% of the variation in the trait being determined by genetic factors, yet the clinical utility of familial screening and genetic testing in unselected cohorts remains poorly defined/examined. Current European...
J. Bruhn, J. Norsk, A. Sillesen et al.· European Heart Journal· 0 citations
Background and Aims: We examined familial patterns and phenotypes of thoracic aortic aneurysms and dissections (TAAD) in the 3746 patients currently populating our Yale Aortic Institute Database. Methods: Patient charts and electronic medical records were retrospectively reviewed for the entire cohort. TAAD disease was...
Lisa C. Harling, Mohammad A. Zafar, Mah I. Kan Changez et al.· Genes· 0 citations
Hypertrophic cardiomyopathy (HCM) is characterized by marked clinical and genetic heterogeneity, which makes early identification of affected relatives and prevention of sudden cardiac death (SCD) central components of care. This narrative review examines how family screening, SCD risk stratification, and contemporary...
F. D. de Souza, Ana Luísa Magnabosco Brandalise, Gustavo Antony da Silva Magalhães· International Health Science...· 0 citations
Despite advances in clinical risk stratification, dilated cardiomyopathy (DCM) remains associated with a substantial risk of malignant ventricular arrhythmias and sudden cardiac death. Genetic testing may provide incremental value in arrhythmic risk assessment and primary prevention implantable cardioverter-defib...
A. Bernabei, A. Paldino, A. Fluca et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.